ImaCor, Inc., the developer of the first and only hemodynamic transesophageal echocardiographic (HTEE™) management system, today announced it has been awarded a Federal Supply Schedule (FSS) contract for the ImaCor ClariTEE® probe by the Department of Veteran Affairs (VA).
The five-year FSS contract supports the delivery of HTEE technology into the critical care centers of the Department of Defense and the VA, one of the largest integrated health care delivery systems in the country with over 170 hospitals.
“We welcome this opportunity to add VA and Department of Defense hospitals to our growing list of civilian customers that are successfully using HTEE technology to address the burden of hemodynamic instability, thereby ensuring improved patient management,” said Peter Pellerito, President and CEO of ImaCor.
The ClariTEE miniaturized transesophageal probe can be placed in a patient for on-demand imaging over an extended period of time. This disposable TEE probe is the first of its kind in the world, enabling direct visualization of cardiac function in critically ill patients. It provides gold standard TEE hemodynamic assessmentindwelling for up to 72 hours, supporting both optimal patient care and reduced care costs.
ImaCor Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures, and distributes advanced solutions for hemodynamic assessment in the critical care environment for the purpose of improving patient outcomes and optimizing utilization of healthcare costs. ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling TEE probe suitable for long-term clinical settings. hTEE™, Zura™ and ClariTEE® are trademarks of ImaCor, Inc. http://www.imacorinc.com.